For parents of children with autism and clinicians advising them, two hotly debated interventions are converging into a single urgent question: what does the evidence actually support? This review arrives at a moment when families face a flood of conflicting claims, and its conclusions carry meaningful practical weight for prenatal and pediatric decision-making.
On folinic acid (leucovorin), several small randomized trials have documented short-term gains in verbal and social communication, with effect sizes appearing most pronounced among children who test positive for folate receptor autoantibodies (FRAA) — a biological subgroup that may have impaired folate transport across the blood-brain barrier. However, the evidence base is fragile: studies are single-center, sample sizes are limited, and outcome measures vary substantially across trials. Critically, a 2024 randomized trial was retracted in January 2026, underscoring that early positive findings in this field can collapse under scrutiny. On prenatal acetaminophen, a Swedish cohort encompassing nearly 2.5 million births — with sibling-controlled analysis to strip out shared familial confounding — found no association with autism, ADHD, or intellectual disability, representing among the most methodologically robust data yet published on this question.
The FRAA subgroup finding for folinic acid is scientifically plausible and aligns with earlier pilot work by Frye and colleagues, but replication in larger, multi-center, double-blind trials is essential before clinical recommendations can follow. The acetaminophen exoneration matters enormously: prior observational studies linking prenatal exposure to neurodevelopmental outcomes were likely confounded by indication — mothers with more pain or inflammatory conditions use more acetaminophen, and those conditions themselves carry risk. The sibling design elegantly controls for this. Overall, this review is confirmatory rather than paradigm-shifting, but its clear-eyed synthesis is exactly what clinicians need to counter misinformation circulating in autism parent communities.